Amarin Corporation plc (AMRN)
NASDAQ: AMRN · Real-Time Price · USD
13.60
-0.20 (-1.45%)
At close: Dec 22, 2025, 4:00 PM EST
13.65
+0.05 (0.37%)
After-hours: Dec 22, 2025, 7:39 PM EST
Amarin Corporation Employees
Amarin Corporation had 275 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
275
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$824,484
Profits / Employee
-$313,425
Market Cap
282.78M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 275 | 0 | - |
| Dec 31, 2023 | 275 | -90 | -24.66% |
| Dec 31, 2022 | 365 | -195 | -34.82% |
| Dec 31, 2021 | 560 | -440 | -44.00% |
| Dec 31, 2020 | 1,000 | 35 | 3.63% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AMRN News
- 6 weeks ago - New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients - GlobeNewsWire
- 7 weeks ago - Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 - GlobeNewsWire
- 7 weeks ago - Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress - GlobeNewsWire
- 3 months ago - Amarin: Vascepa's Global Pivot From U.S. Squeeze To International Boom - Seeking Alpha
- 4 months ago - Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025 - GlobeNewsWire
- 4 months ago - New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups - GlobeNewsWire
- 4 months ago - New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025 - GlobeNewsWire